Bio-Rad's Q2 Revenues Slip 2 Percent on Softness in Europe, Strengthening Dollar | GenomeWeb

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories said after the close of the market on Tuesday that revenues in the second quarter were down 2 percent year over year, as the firm missed analysts' estimate on the top line.

For the three months ended June 30, the Hercules, Calif.-based company recorded revenues of $510.4 million, down from $521.7 million and below the consensus Wall Street estimate of $524.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.